Exelixis

EXEL

Market cap $11.4B

Exelixis is looking to break out beyond its cabozantinib franchise. The company reported big earnings growth in 2025.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, March 10 in Miami. 2026 Citizens Life Scie.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?

Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.

Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.